These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9081967)

  • 1. Gamma interferon in the treatment of Kala-azar and other forms of Leishmaniasis.
    Sundar S; Murray HW
    J Assoc Physicians India; 1995 May; 43(5):348-50. PubMed ID: 9081967
    [No Abstract]   [Full Text] [Related]  

  • 2. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
    Murray HW; Delph-Etienne S
    J Infect Dis; 2000 Feb; 181(2):795-9. PubMed ID: 10669380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
    Musa AM; Khalil EA; Mahgoub FA; Elgawi SH; Modabber F; Elkadaru AE; Aboud MH; Noazin S; Ghalib HW; El-Hassan AM;
    Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on: Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.
    de Górgolas M
    Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):1054; author reply 1054-5. PubMed ID: 17651771
    [No Abstract]   [Full Text] [Related]  

  • 8. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable.
    Bhattacharya SK; Sur D; Sinha PK; Karbwang J
    Indian J Med Res; 2006 Mar; 123(3):195-6. PubMed ID: 16778303
    [No Abstract]   [Full Text] [Related]  

  • 10. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Leishmaniasis treatment].
    Minodier P; Jurquet AL; Noël G; Uters M; Laporte R; Garnier JM
    Arch Pediatr; 2010 Jun; 17(6):838-9. PubMed ID: 20654919
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Ansari NA; Jain RK; Salotra P
    Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
    [No Abstract]   [Full Text] [Related]  

  • 13. Visceral leishmaniasis (kala-azar) and pregnancy.
    Figueiró-Filho EA; Duarte G; El-Beitune P; Quintana SM; Maia TL
    Infect Dis Obstet Gynecol; 2004; 12(1):31-40. PubMed ID: 15460194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
    Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
    Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
    [No Abstract]   [Full Text] [Related]  

  • 15. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
    Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
    Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of treatment with interferon-gamma alone in visceral leishmaniasis.
    Sundar S; Murray HW
    J Infect Dis; 1995 Dec; 172(6):1627-9. PubMed ID: 7594733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
    Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
    Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral miltefosine in the treatment of kala-azar.
    Mohan A; Seth S
    Natl Med J India; 2000; 13(4):202-3. PubMed ID: 11002688
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis.
    Ansari NA; Ramesh V; Salotra P
    Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1160-2. PubMed ID: 18639311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.